Techniques to elucidate the conformation of prions

Martin L Daus

Martin L Daus, ZBS6 - Proteomics and Spectroscopy, Robert Koch-Institute, 13353 Berlin, Germany

Author contributions: Daus ML wrote the paper.

Supported by Alberta Prion Research Institute, Canada (Project title: “Comprehensive Risk Assessment of CWD Transmission to Humans Using Non-human Primates”); and European Metrology Research Programme (EMRP); Researcher Grant: HLT10-BiOrigin (Metrology for the Biomolecular Origin of Disease).

Conflict-of-interest statement: The author declares no conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Dr. Martin L Daus, ZBS6 - Proteomics and Spectroscopy, Robert Koch-Institute, Seestrasse 10, 13353 Berlin, Germany. dauwm@rki.de
Telephone: +49-30-187542844
Fax: +49-30-187542664

Received: March 11, 2015
Peer-review started: March 16, 2015
First decision: April 27, 2015
Revised: May 10, 2015
Accepted: June 15, 2015
Article in press: June 16, 2015
Published online: August 26, 2015

Abstract

Proteinaceous infectious particles (prions) are unique pathogens as they are devoid of any coding nucleic acid. Whilst it is assumed that prion disease is transmitted by a misfolded isoform of the cellular prion protein, the structural insight of prions is still vague and research for high resolution structural information of prions is still ongoing. In this review, techniques that may contribute to the clarification of the conformation of prions are presented and discussed.

Key words: Prion; Amyloid; Neurodegenerative disease; Protein structure; Fourier-transform infrared spectroscopy

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Prions (proteinaceous infectious particles) are misfolded isoforms of cellular proteins that cause neurodegenerative diseases in mammals and humans. Several structural models are available for prions but a 3D-structure does still not exist. More structural information is demanded for the understanding of the conversion process and finally for the design of efficient therapeutic approaches. In this review, techniques that may contribute to the clarification of the conformation of prions are presented.

Daus ML. Techniques to elucidate the conformation of prions. World J Biol Chem 2015; 6(3): 218-222 Available from: URL: http://www.wjgnet.com/1949-8454/full/v6/i3/218.htm DOI: http://dx.doi.org/10.4331/wjbc.v6.i3.218

INTRODUCTION

Prions are infectious proteins that cause fatal neurodegenerative diseases[1-5]. Rearrangements of the structure of the cellular prion protein (PrP\(^\text{C}\)) are the key of infection. PrP\(^\text{C}\) is characterized by a high \(\alpha\)-helical content and conversion in a \(\beta\)-sheet rich conformer (PrP\(^\text{SC}\)) transforms it into an infectious protein[6,7]. According to the “prion hypothesis” the protein itself is the causative agent of disease even though several cofactors that may influence the conversion process are discussed in the literature[8-12]. A 3D-structure of PrP\(^\text{Sc}\) does still not exist, albeit several structural models for
PrPCSc are described\(^{13}\). Definite structural information about prions is indispensable for the understanding of the conversion process and eventually for the design of new therapeutic strategies.

In the present review, several techniques to assess the conformation of prions are presented and discussed with a main focus on the application of Fourier-transform infrared spectroscopy. The intention of this mini-review article is to give an overview of current techniques used in prion research to elucidate the structure of prions. For details readers are referred to the literature cited in the text.

FOURIER-TRANSFORM INFRARED SPECTROSCOPY

Fourier-transform infrared (FTIR) spectroscopy was one of the fundamental techniques that had demonstrated the high \(\beta\)-sheet content of PrPCSc in contrast to PrPC\(^{14-16}\). This technique has several advantages compared to other analytical approaches. With FTIR spectroscopy protein samples can be analyzed (1) without labeling; (2) under native conditions; (3) with only minute amounts of material (in particular in case of micro-FTIR); and (4) in a dynamic process. Moreover, results can be obtained within a very short time\(^{16,17}\). FTIR spectroscopy elucidates primarily the secondary structure of proteins and originates essentially from C=O stretching vibrations of the amide groups of the protein backbone. For the structural characterization of PrPCSc, the amide I band is the most useful infrared absorption band\(^{18-20}\).

FTIR of proteins typically is performed in H\(_2\)O, D\(_2\)O or under dried conditions. For spectroscopic analyses the purity of sample material is of utmost importance\(^{16,21}\). This is particularly challenging when sample material has to be extracted from infected tissue and when the protein of interest is present in only small amounts. Improved purification protocols for the extraction of prions from tissue have been published and allowed us to analyze tiny amounts of sample material by micro-FTIR\(^{16}\). Micro-FTIR can be applied on dried protein samples using a FTIR spectrometer linked to an IR-microscope. This enables the performance of measurements on pure protein samples in the range of only a few nanograms.

Micro-FTIR has been shown to be an appropriate tool for the screening of different prion strains and in vitro generated prion protein (PrP\(^{\text{PrP}}\))\(^{16,17}\). Particularly in case of in vitro generated PrP only very small amounts of prions are expected to be extractable. This could impede an analysis by other structure-sensitive techniques [e.g., circular dichroism (CD) spectroscopy]. We recently recorded spectra from PrP\(^{\text{Sc}}\) molecules generated by protein misfolding cyclic amplification (PMCA) using micro-FTIR\(^{16}\). PMCA mimics the conversion of PrP\(^{\text{C}}\) to PrP\(^{\text{Sc}}\) in vitro\(^{22,23}\). Comparing spectra from native- and PMCA-derived PrP\(^{\text{Sc}}\) revealed structural differences of molecules before and after PMCA. This technical progress provides the possibility to analyze the influence of cofactors on the conversion activity and putative correlating structural rearrangements in future experiments.

As mentioned above, micro-FTIR is also suitable to discriminate different prion strains\(^{14,24,25}\). In prion research, strains are defined as prion-isolates that, after inoculation into distinct hosts, cause disease with consistent characteristics, such as incubation period, distinct patterns of PrP\(^{\text{Sc}}\) distribution and spongiosis in the brain (Figure 1). A concrete example of use would be strain typing for chronic wasting disease (CWD)\(^{27}\). CWD is a prion disease occurring in cervids in North America and rapidly spreads among free ranging deer and elk\(^{26,27}\). To test whether and to which extent there are different strains for CWD in the environment or whether new strains emerge in the future, micro-FTIR (with only 100 mg of infected tissue needed to obtain a sufficient amount of protein extract for FTIR analysis) can be applied. The use of small amounts of sample material allows the preparation of multiple samples within a short time. Spectra from CWD field samples collected in the past, present or future could be compared. As different strains can correlate with different zoonotic potentials a rapid structural scan by FTIR may be suitable for a proper risk assessment.

OTHER TECHNIQUES TO DETERMINE THE STRUCTURE OF PRIONS

Electron microscopy analyses directly reveal the morphological difference between PrP\(^{\text{C}}\) and PrP\(^{\text{Sc}}\) as the latter appears as amyloid fibrils\(^{28,29}\). Moreover, it is possible to distinguish between some prion strains due to their distinct morphological shape. Electron crystallography had a limited scope to predict general conformational features because prions tend to aggregate\(^{30,31}\). Atomic force microscopy (AFM) is used as an alternative technique that needs no staining of samples\(^{16,32}\). AFM can be combined with infrared- and Raman-spectroscopy suitable for site-directed sample characterization. Tip enhanced infrared- or Raman-spectroscopy principally allow measurements on defined positions within a prion fibril\(^{33,34}\). These techniques could be useful for the analyses of mixtures of prion fibrils (“quasi species”) and would allow a precise biochemical characterization of prions\(^{17,35}\).

The impact of specific amino acids on the prion conversion process can be determined by mutational analyses when subsequently tested in animal- or cell culture- or in vitro conversion assays\(^{36-39}\). By this means it could be demonstrated that specific amino acids accelerate or decelerate the conversion process and that the N-terminus is not essential for prion infectivity\(^{40}\). Limited proteolysis with Proteinase K is used to discriminate PrP\(^{\text{C}}\) from PrP\(^{\text{Sc}}\) as the conversion in a \(\beta\)-sheet rich conformation (PrP\(^{\beta\-sheet}\)) prevents the
C-terminus from degradation while the less structured N-terminus is cleaved off. Limited proteolysis at different pH values, with rising amounts of protease or in the presence of chaotropic salts can give further structural information and may help to discriminate prion strains with different conformations.

Recombinant PrP can (after site-directed mutagenesis) site-specifically be labelled with fluorophores or spin labels and then analyzed by fluorescence- or EPR spectroscopy, respectively. Such studies propose a parallel in-register β-sheet structure of PrP amyloids and enable the calculation of distances between specific residues within an amyloid fibril. It has to be mentioned that misfolded recombinant PrP without the addition of cofactors usually lacks infectivity and may therefore not exactly represent the in vivo structure of PrPSC.

The exchange of hydrogen for deuterium ions and subsequent analysis by mass spectrometry allows the detection of unstructured and highly structured regions within PrPSC. The C-terminal part of prions shows low exchange rates indicating a highly structured conformation.

While the above mentioned techniques reveal basic and to some extent indirect structural insights, high resolution structure information is needed to understand the conversion process of PrP. High resolution 3D-structural data from X-ray fiber diffraction and NMR are available for PrP but not for the complete PrPSC molecule. Because of the insolubility and the propensity to aggregate only parts of PrPSC are structurally resolved until now.

**CONCLUSION**

Misfolding of a cellular protein into an infectious isoform sharing the same primary structure is unique for prions. This phenomenon is currently discussed to be a general principle for other neurodegenerative diseases. Prions lack a coding nucleic acid thus diagnosis and the detection of misfolded isoforms cannot be done by genetics but e.g., by structural characterization.

A lot of structural models for PrPSC exist but as discussed recently by Requena and Wille the results and/or their interpretation remain controversial. For a better understanding of the conversion of PrP to PrPSC, more structural data from biochemical and biophysical experiments are required for PrPSC (Figure 1). Therapeutic strategies that aim at the prevention of this misfolding process would benefit from such a progress.

**REFERENCES**

1. Prusiner SB. DeArmond SJ. Prions causing nervous system degeneration. Lab Invest 1987; 56: 349-363 [PMID: 2882063]
2. Prusiner SB. Novel proteinaceous infectious particles cause scrapie.
Daus ML. Structure determination of prions.
Daus ML. Structure determination of prions

[PMID: 15933194 DOI: 10.1126/science.1110837]

Prigent S, Rezaei H. PrP assemblies: spotting the responsible regions in prion propagation. Proc Natl Acad Sci USA 2011; 108: 69-74 [PMID: 21878288 DOI: 10.1073/pnas.1011532108]

Hubbard SJ. The structural aspects of limited proteolysis of native proteins. Biochim Biophys Acta 1998: 1382: 191-206 [PMID: 9540791 DOI: 10.1016/S0167-4888(97)00175-1]

Kocisko DA, Lansbury PT, Coughy B. Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry 1996; 35: 13434-13442 [PMID: 8873621 DOI: 10.1021/bi9610562]

Zou WQ, Capelliari S, Parchi P, Sy MS, Gambetti P, Chen SG. Identification of novel protease K-resistant C-terminal fragments of PrP in Creutzfeld-Jakob disease. J Biol Chem 2003; 278: 40429-40436 [PMID: 12917418 DOI: 10.1074/jbc.M308550200]

Zanusso G, Farinazzo A, Prelli F, Fiorini M, Gelati M, Ferrari S, Righetti PG, Rizzuto N, Frangione B, Monaco S. Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. J Biol Chem 2004; 279: 38936-38942 [PMID: 15247220 DOI: 10.1074/jbc.M405468200]

Sajnani G, Pastrana MA, Dynin I, Onisko B, Requena JR. Scrapie prion protein structural constraints obtained by limited proteolysis and mass spectrometry. J Mol Biol 2008; 382: 88-98 [PMID: 18621059 DOI: 10.1016/j.jmb.2008.06.070]

Vázquez-Fernández E, Alonso J, Pastrana MA, Ramos A, Sitz L, Vidal E, Dynin I, Petch B, Silva CJ, Requena JR. Structural organization of mammalian prions as probed by limited proteolysis. PLoS One 2012; 7: e50111 [PMID: 23185550 DOI: 10.1371/journal.pone.0050111]

Cobb NJ, Sönntuchsen FD, McHaourab H, Surewicz WK. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure. Proc Natl Acad Sci USA 2007; 104: 18946-18951 [PMID: 18025469 DOI: 10.1073/pnas.0706522104]

Seidel R, Engellhard M. Chemical biology of prion protein: tools to bridge the in vitro/vivo interface. Top Curr Chem 2011; 305: 199-223 [PMID: 21769714 DOI: 10.1007/128_2011_201]

Ngo S, Chiang V, Guo Z. Quantitative analysis of spin exchange interactions to identify β strand and turn regions in Ure2 prion domain fibrils with site-directed spin labeling. J Struct Biol 2012; 180: 374-381 [PMID: 22297940 DOI: 10.1016/j.jsb.2012.08.008]

Smirnovs V, Kim J, Lu X, Atarashi R, Caughey B, Surewicz WK. Distinct structures of scrapie prion protein (PrPSc)-seeded versus spontaneous recombinant prion protein fibrils revealed by hydrogen/deuterium exchange. J Biol Chem 2009; 284: 24233-24241 [PMID: 19596861 DOI: 10.1074/JBC.M109.036558]

Nazarbali A, Hornemann S, Aguzzi A, Zenobi R. Hydrogen/deuterium exchange mass spectrometry identifies two highly protected regions in recombinant full-length prion protein amyloid fibrils. J Mass Spectrom 2009; 44: 965-977 [PMID: 19283723 DOI: 10.1002/jms.1572]

Lu X, Wintrode PL, Surewicz WK. Beta-sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange. Proc Natl Acad Sci USA 2007; 104: 1510-1515 [PMID: 17242357 DOI: 10.1073/pnas.0608447104]

Smirnovs V, Baron GS, Offerdahl DK, Raymond GJ, Caughey B, Surewicz WK. Structural organization of brain-derived mammalian prions examined by hydrogen-deuterium exchange. Nat Struct Mol Biol 2011; 18: 504-506 [PMID: 21441913 DOI: 10.1038/nsmb.2035]

Meier BH, Böckmann A. The structure of fibrils from 'misfolded' proteins. Curr Opin Struct Biol 2015; 30: 43-49 [PMID: 25544255 DOI: 10.1016/j.sbi.2014.12.001]

Nguyen JT, Inouye H, Baldwin MA, Fletterick RJ, Cohen FE, Prusiner SB, Kirschner DA. X-ray diffraction of scrapie prion rods and PrP peptides. J Mol Biol 1995; 252: 412-422 [PMID: 7563061 DOI: 10.1006/jmbi.1995.0507]

Wille H, Bian W, McDonald M, Kendall A, Colby DW, Bloch L, Ollesch J, Borovinsyki AL, Cohen FE, Prusiner SB, Stubbis G. Natural and synthetic prion structure from X-ray fiber diffraction. Proc Natl Acad Sci USA 2009; 106: 16990-16995 [PMID: 19805070 DOI: 10.1073/pnas.0909006106]

Wasmser C, Lange A, Van Mielkebeke H, Siemer AB, Rick R, Meier BH. Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. Science 2008; 319: 1523-1526 [PMID: 18339938 DOI: 10.1126/science.1151839]

Moraes R, Callegari K, Soto C. Prion-like features of misfolded Aβ and tau aggregates. Virus Res 2015; Epub ahead of print [PMID: 25575736 DOI: 10.1016/j.viruses.2014.12.031]

Beeke M, Thomzig A, Schulz-Schaeffer WJ, Burger R. Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? Acta Neuropathol 2014; 128: 463-476 [PMID: 25073522 DOI: 10.1007/s00401-014-1324-9]

Ashe KH, Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 2013; 7: 55-59 [PMID: 23208281 DOI: 10.4161/pri.23061]

Acevedo-Morantes CY, Wille H. The structure of human prions: from biology to structural models-considerations and pitfalls. Viruses 2014; 6: 3875-3892 [PMID: 25333467 DOI: 10.3390/v6103875]
